March 09, 2017
2 min watch

VIDEO: DBV Technologies VP discusses peanut allergy patch, other company products and trials

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ATLANTA — Luis Salmun, MD, senior vice president, global medical affairs, DBV Technologies, outlined some of the projects in the company’s pipeline to help patients with several different types of allergic reactions at the annual meeting of the American Academy of Allergy, Asthma & Immunology. He also discussed the results in the VIPES extension trial involving the company’s peanut patch.  

"We have observed in this trial a progressive increase in the efficacy of this product from 53% efficacy on our endpoints at the end of year 1, up to 83.3% after 3 years of treatment.”